Total Payments
$589,846
2024 Payments
$39,800
Companies
27
Transactions
224
Medicare Patients
5,193
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$527,364 (89.4%)
Consulting$47,763 (8.1%)
Travel$8,125 (1.4%)
Food & Beverage$5,825 (1.0%)
Education$750.00 (0.1%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Acquisitions | $340,087 | 1 | 57.7% |
| Current or prospective ownership or investment interest | $158,645 | 8 | 26.9% |
| Consulting Fee | $47,763 | 12 | 8.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,442 | 11 | 4.8% |
| Travel and Lodging | $8,125 | 25 | 1.4% |
| Food and Beverage | $5,825 | 152 | 1.0% |
| Education | $750.00 | 1 | 0.1% |
| Entertainment | $107.13 | 2 | 0.0% |
| Grant | $83.33 | 1 | 0.0% |
| Gift | $19.40 | 1 | 0.0% |
| Unspecified | $0 | 10 | 0.0% |
Payments by Type
General
$589,846
214 transactions
Ownership
$0
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $498,735 | 20 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $46,016 | 35 | $0 (2024) |
| Spark Therapeutics, Inc. | $35,365 | 26 | $0 (2021) |
| Biogen, Inc. | $4,128 | 15 | $0 (2024) |
| Allergan, Inc. | $1,106 | 11 | $0 (2021) |
| Genentech USA, Inc. | $966.53 | 28 | $0 (2022) |
| Genentech, Inc. | $786.27 | 11 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $549.21 | 23 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $331.26 | 14 | $0 (2020) |
| Alimera Sciences, Inc. | $247.26 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,800 | 14 | Janssen Pharmaceuticals, Inc ($39,590) |
| 2023 | $7,544 | 63 | Janssen Pharmaceuticals, Inc ($6,426) |
| 2022 | $11,059 | 22 | US Retina LLC ($6,665) |
| 2021 | $360,434 | 21 | US Retina LLC ($356,640) |
| 2020 | $54,889 | 20 | US Retina LLC ($49,469) |
| 2019 | $62,488 | 45 | US Retina LLC ($47,071) |
| 2018 | $53,139 | 25 | US Retina LLC ($38,891) |
| 2017 | $494.49 | 14 | Alimera Sciences, Inc. ($165.08) |
All Payment Transactions
224 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/29/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 07/29/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 07/29/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 07/11/2024 | Biogen, Inc. | BYOOVIZ (Biological) | Food and Beverage | In-kind items and services | $143.26 | General |
| Category: Ophthalmology | ||||||
| 06/18/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 06/18/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 06/18/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 03/12/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug), VISUDYNE, RETISERT | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Ophthalmology | ||||||
| 02/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: EYE CARE | ||||||
| 02/07/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 02/07/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 02/07/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 02/07/2024 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| 01/16/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $123.68 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $123.68 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $123.68 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $123.68 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $55.00 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 12/10/2023 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 12/09/2023 | Janssen Pharmaceuticals, Inc | — | Travel and Lodging | In-kind items and services | $196.66 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,335 | 3,926 | $2.9M | $982,543 |
| 2022 | 12 | 1,120 | 3,542 | $2.9M | $1.1M |
| 2021 | 12 | 1,248 | 3,723 | $2.3M | $881,124 |
| 2020 | 11 | 1,490 | 3,824 | $2.4M | $898,700 |
Total Patients
5,193
Total Services
15,015
Medicare Billing
$3.8M
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 86 | 1,088 | $2.1M | $754,206 | 36.7% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 20 | 290 | $183,848 | $62,609 | 34.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 134 | 627 | $256,650 | $60,225 | 23.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 292 | 392 | $128,968 | $36,403 | 28.2% |
| 92134 | Imaging of retina | Office | 2023 | 360 | 931 | $97,755 | $28,794 | 29.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 68 | 82 | $27,142 | $9,238 | 34.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 23 | 84 | $25,740 | $6,470 | 25.1% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 75 | 106 | $13,250 | $5,288 | 39.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $15,408 | $4,819 | 31.3% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 42 | 42 | $16,338 | $4,645 | 28.4% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 61 | 87 | $8,439 | $3,366 | 39.9% |
| 92250 | Photography of the retina | Office | 2023 | 82 | 89 | $9,256 | $2,081 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 19 | $6,251 | $1,531 | 24.5% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 16 | 19 | $4,427 | $1,422 | 32.1% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 17 | 18 | $2,952 | $821.36 | 27.8% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 11 | 16 | $2,016 | $624.95 | 31.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 95 | 1,270 | $2.4M | $912,572 | 38.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 114 | 642 | $208,620 | $62,028 | 29.7% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 254 | 353 | $101,509 | $30,817 | 30.4% |
| 92134 | Imaging of retina | Office | 2022 | 166 | 624 | $59,147 | $19,358 | 32.7% |
| 92250 | Photography of the retina | Office | 2022 | 271 | 379 | $39,416 | $10,496 | 26.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 59 | 68 | $17,714 | $7,062 | 39.9% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 46 | 89 | $27,300 | $6,723 | 24.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 45 | 46 | $9,545 | $3,014 | 31.6% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 27 | 27 | $9,713 | $2,951 | 30.4% |
About Dr. Alan Kimura, MD
Dr. Alan Kimura, MD is a Ophthalmology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851343214.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Kimura, MD has received a total of $589,846 in payments from pharmaceutical and medical device companies, with $39,800 received in 2024. These payments were reported across 224 transactions from 27 companies. The most common payment nature is "Acquisitions" ($340,087).
As a Medicare-enrolled provider, Kimura has provided services to 5,193 Medicare beneficiaries, totaling 15,015 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Denver, CO
- Active Since 05/16/2006
- Last Updated 03/10/2020
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1851343214
Products in Payments
- LUXTURNA (Biological) $35,365
- Lucentis (Biological) $1,223
- EYLEA (Biological) $473.91
- OZURDEX (Drug) $378.55
- SUSVIMO (Drug) $288.06
- Cimerli (Biological) $231.29
- YUTIQ (Drug) $186.86
- Iluvien (Biological) $165.08
- Syfovre (Drug) $164.58
- VABYSMO (Drug) $152.71
- EYLEA AFLIBERCEPT INJECTION (Biological) $150.71
- BEOVU (Drug) $144.99
- BYOOVIZ (Biological) $143.26
- EVA Ophthalmic Surgical System (Device) $127.77
- XIPERE (Drug) $87.18
- P200DTx (Device) $86.26
- EYLEA HD (Biological) $75.30
- STELLARIS PC (Device) $75.00
- XR (Device) $73.80
- ILUVIEN (Drug) $44.41
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Denver
Mr. Jerry Popham, M.d, M.D
Ophthalmology — Payments: $799,779
Ophthalmology $799,779
Jack Zamora, Md, MD
Ophthalmology — Payments: $666,046
Ophthalmology $666,046
Dr. Cristos Ifantides, M.d, M.D
Ophthalmology — Payments: $143,630
Ophthalmology $143,630
Brian Joondeph, Md, MD
Ophthalmology — Payments: $108,464
Ophthalmology $108,464
Dr. Eva Kim, Md, MD
Ophthalmology — Payments: $65,451
Ophthalmology $65,451
Dr. Michael Jansen, M.d, M.D
Ophthalmology — Payments: $44,975
Ophthalmology $44,975